R&D Projects development to biotechnology and pharmaceutical companies
OWL Genomics has established a state-of-the-art mass spectrometry based metabolomics platform ideally suited to the study of liver disease biomarkers, currently the company’s main research front. In addition to this ongoing research effort, OWL Genomics conducts metabolomic studies for other pharmaceutical and biotechnology companies in key areas such as biomarker discovery, clinical studies, diagnostics and toxicology.
OWL Genomics strives to provide a top quality service for cutting-edge research, using strictly controlled analytical procedures and state-of-the-art facilities under expert supervision.
With this web OWL Genomics intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a qualified
physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 07/29/2010
This site complies with the HONcode standard for trustworthy health information:
verify here.